NASDAQ:MENS

Jyong Biotech Q2 2025 Earnings Results & Report

Jyong Biotech logo
$1.80 +0.03 (+1.69%)
Closing price 04:00 PM Eastern
Extended Trading
$1.82 +0.02 (+1.11%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jyong Biotech reported Q2 2025 earnings on January 9, 2026. The company reported EPS of -$0.01.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes

Jyong Biotech EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Jyong Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Jyong Biotech Q2 2025 Earnings FAQ

Jyong Biotech (NASDAQ:MENS) reported earnings of -$0.01 per share for Q2 2025. The report was announced on Friday, January 9, 2026.

Jyong Biotech Earnings Headlines

Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
See More Jyong Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jyong Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jyong Biotech and other key companies, straight to your email.

About Jyong Biotech

Jyong Biotech (NASDAQ:MENS) is a clinical-stage biopharmaceutical company based in Taiwan that develops treatments for urological diseases. Its research focuses on botanical drug candidates, including therapies for conditions affecting the prostate and urinary system.

The company’s pipeline includes MCS-2, a botanical drug candidate being developed for benign prostatic hyperplasia, a noncancerous enlargement of the prostate. Jyong Biotech is also developing other candidates for urological conditions.

Jyong Biotech was established in Taiwan and conducts drug development activities there. Its focus is on advancing its pipeline through clinical development; its candidates are investigational and are not established treatments.

View Jyong Biotech Profile